Investigating Epcoritamab for Follicular Lymphoma and Beyond With Reid Merryman, MD

(5:36)

Three-year update on the EPCORE NHL-1 trial of epcoritamab in R/R DLBCL

(2:19)

Follow-up results of EPCORE NHL-1: subcutaneous epcoritamab in R/R LBCL

(1:49)

Exploring the Approval of Epcoritamab for Diffuse Large B-Cell Lymphoma With Reid Merryman, MD

(5:57)

Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma

(36)

Dr Nowakowski on the EPCORE NHL-1 Trial Results of Epcoritamab in R/R Follicular Lymphoma

(2:30)

New DLBCL Clinical Trial: Epcoritamab for Diffuse Large B-Cell Lymphoma

(1:9)

Subcutaneous epcoritamab in R/R B-cell NHL

(2:42)

Comparative effectiveness of epcoritamab versus real-world usual care in R/R follicular lymphoma

(2:26)

Results of Phase I/II study of epcoritamab+R-DHAX/C in patients with R/R DLBCL eligible for autoSCT

(2:42)

Dr Nowakowski on the FDA Approval of Epcoritamab in R/R Follicular Lymphoma

(1:6)

Phase II study of epcoritamab in R/R LBCL

(1:38)

Epcoritamab (Epkinly), a novel bispecific antibody to target cancer cells

(3:32)

EPCORE NHL-1 subgroup analyses: epcoritamab monotherapy in patients with R/R LBCL

(1:46)

Epcoritamab versus mosunetuzumab in patients with R/R FL: findings of a MAIC

(2:16)

The use of targeted drug therapy for aggressive lymphoma

(1:30)

The role of epcoritamab in third-line or later LBCL

(3:9)

Epcoritamab in R/R FL: pooled efficacy data from EPCORE NHL-1

(1:28)

Epcoritamab for R/R FL: Matthew Hadfield, Alankrita Taneja, Tahi Ahmadi, and Jacqueline Nielsen

(28:10)